Bukwang Pharm Cash Flow-to-Debt Ratio
Bukwang Pharm cash flow-to-debt ratio. Bukwang Pharm (003000) has a Cash Flow-to-Debt Ratio of -0.05x as of September 2025, meaning its operating cash flow of ₩-6.24 Billion could theoretically repay 0% of its total liabilities (₩132.16 Billion) in one year. Check how high is Bukwang Pharm's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Bukwang Pharm (2007–2024)
Cash flow-to-debt ratio of Bukwang Pharm from 2007 to 2024. Historical debt coverage capacity for Bukwang Pharm across 13 annual periods. Check how aggressively does Bukwang Pharm reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Bukwang Pharm Cash Flow-to-Debt Ratio by Year (2007–2024)
Bukwang Pharm cash flow-to-debt ratio by year from 2007 to 2024. Year-by-year debt coverage analysis for Bukwang Pharm. For the full cash flow conversion analysis, see Bukwang Pharm (003000) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.27x | ₩34.36 Billion | ₩129.03 Billion | ▲ +654.0% |
| 2023 | -0.05x | ₩-9.36 Billion | ₩194.75 Billion | ▼ -137.7% |
| 2022 | 0.13x | ₩16.46 Billion | ₩129.08 Billion | ▼ -43.6% |
| 2021 | 0.23x | ₩26.52 Billion | ₩117.36 Billion | ▲ +3956.1% |
| 2020 | 0.01x | ₩723.17 Million | ₩129.78 Billion | ▲ +101.5% |
| 2019 | -0.38x | ₩-23.41 Billion | ₩62.05 Billion | ▼ -543.7% |
| 2018 | 0.09x | ₩6.82 Billion | ₩80.17 Billion | ▼ -75.2% |
| 2017 | 0.34x | ₩8.56 Billion | ₩24.93 Billion | ▲ +201.8% |
| 2016 | -0.34x | ₩-7.76 Billion | ₩23.00 Billion | ▼ -193.4% |
| 2015 | 0.36x | ₩10.30 Billion | ₩28.51 Billion | ▼ -65.2% |
| 2014 | 1.04x | ₩27.86 Billion | ₩26.82 Billion | ▼ -22.8% |
| 2013 | 1.35x | ₩36.52 Billion | ₩27.14 Billion | ▲ +114.3% |
| 2007 | 0.63x | ₩27.87 Billion | ₩44.39 Billion | — |